home / stock / hook / hook news


HOOK News and Press, HOOKIPA Pharma Inc. From 05/30/22

Stock Information

Company Name: HOOKIPA Pharma Inc.
Stock Symbol: HOOK
Market: NASDAQ
Website: hookipapharma.com

Menu

HOOK HOOK Quote HOOK Short HOOK News HOOK Articles HOOK Message Board
Get HOOK Alerts

News, Short Squeeze, Breakout and More Instantly...

HOOK - Morgan Stanley updates biotechs with negative enterprise values & 2022 catalysts

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...

HOOK - HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO

Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and neck cancer patients Poster presentation to include data supporting recommended Phase ...

HOOK - HOOKIPA Pharma GAAP EPS of -$0.40 misses by $0.19, revenue of $1.44M misses by $13.09M

HOOKIPA Pharma press release (NASDAQ:HOOK): Q1 GAAP EPS of -$0.40 misses by $0.19. Revenue of $1.44M (-72.8% Y/Y) misses by $13.09M. For further details see: HOOKIPA Pharma GAAP EPS of -$0.40 misses by $0.19, revenue of $1.44M misses by $13.09M

HOOK - HOOKIPA Pharma Reports First Quarter 2022 Financial Results and Recent Highlights

HB-200 program on track to report Phase 1 data mid-year, Phase 2 data in combination with pembrolizumab in second half of 2022 Q1 capital raise and Gilead collaboration funding generated a strong cash position of $142 million NEW YORK and VIENNA, Austria, May 16, 2022 (GLOBE N...

HOOK - HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022

NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2022 financial ...

HOOK - HOOKIPA Pharma promotes business chief to COO role

HOOKIPA Pharma (NASDAQ:HOOK) promoted Christine D. Baker to COO, effective immediately; Christine joined HOOKIPA in August 2019 as Chief Business Officer and has played a critical role in securing several strategic business collaborations for HOOKIPA's novel arenavira...

HOOK - HOOKIPA announces promotion of Christine D. Baker to Chief Operating Officer

NEW YORK and VIENNA, Austria, May 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the promotion of Christine D. Baker to Chief Opera...

HOOK - HOOKIPA Pharma Appoints Tim Reilly, Ph.D. to its Board of Directors

NEW YORK and VIENNA, Austria, April 20, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Tim Reilly, Ph.D. to its Boar...

HOOK - Hookipa stock rises 12% on pre-clinical data related to cancer drug platform

Hookipa Pharma's (NASDAQ:HOOK) stock rose April 13 after it said that preclinical data showed its arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens. The company said that preclinical data presented at AACR (abstract #4198) sho...

HOOK - New data show HOOKIPA's arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens

Preclinical data on combination with co-stimulatory 4-1BB agonists or adoptive T cell transfer showed potent T cell responses and significant tumor control Preclinical data also expand evidence on arenaviral immunotherapy targeting tumor self-antigens, reinforcing scientific appro...

Previous 10 Next 10